Mounjaro and Ozempic are different medications. Mounjaro contains tirzepatide, which activates two gut hormone receptors (GLP-1 and GIP), while Ozempic contains semaglutide, which activates only GLP-1. Both are weekly injections for type 2 diabetes, and in head-to-head research tirzepatide has tended to lower blood sugar and body weight more. Their side effects and safety warnings are very similar.
Two Different Active Ingredients
The key distinction is the drug inside the pen. Cleveland Clinic explains that tirzepatide mimics both GLP-1 and GIP, hormones triggered by eating that increase insulin production, while semaglutide mimics only GLP-1. Our guide to what semaglutide is and how it works covers the Ozempic side of the story.
Both drugs improve blood sugar and insulin sensitivity, slow stomach emptying, reduce appetite, and can lead to weight loss, according to the same source.
Approved Uses Compared
Mounjaro is indicated for type 2 diabetes in adults and pediatric patients. In August 2026, the FDA also approved it to reduce major cardiovascular events in adults with type 2 diabetes who are at high risk.
Ozempic is approved for managing type 2 diabetes, for lowering cardiovascular risk in adults with type 2 diabetes and heart disease, and for supporting kidney and cardiovascular health in adults with type 2 diabetes and chronic kidney disease, according to Cleveland Clinic.
Neither brand is the one approved for weight loss. That role belongs to Zepbound for tirzepatide and Wegovy for semaglutide.
Dosing Differences
Because the molecules differ, you cannot compare milligrams between them. Per Lilly’s dosing information, Mounjaro starts at 2.5 mg weekly for four weeks to help your body adjust, then moves to 5 mg, with further 2.5 mg increases after at least four weeks on each dose. The maximum is 15 mg weekly in adults and 10 mg in pediatric patients.
Ozempic’s maximum recommended dose is 2 mg weekly, according to Cleveland Clinic. Both are given once a week by injection, and your provider chooses the dose based on your response and how well you tolerate it.
What the Research Shows
In the SURPASS-2 trial, 1,879 adults with type 2 diabetes took tirzepatide or semaglutide 1 mg for 40 weeks. Average A1C dropped by 2.01% to 2.30% with tirzepatide, compared with 1.86% for semaglutide, and weight loss was significantly greater with tirzepatide.
A large real-world study in JAMA Internal Medicine matched 18,386 adults with overweight or obesity. It found tirzepatide was associated with greater weight loss, with a 6.9 percentage point difference at 12 months. The study was observational, so it shows association, not proof of cause. Cleveland Clinic also notes that head-to-head trials did not use semaglutide’s highest dose.
Side Effects and Safety Warnings
Expect a familiar list. Cleveland Clinic names nausea, vomiting, diarrhea, constipation, abdominal pain, and heartburn as common with both, plus fatigue, headaches, and low blood sugar when combined with insulin or sulfonylureas. Both carry an FDA boxed warning for thyroid C-cell tumors, should be avoided in severe gastroparesis, and are not recommended during pregnancy.
Do not combine them. Healthline says not to use Ozempic with other semaglutide or GLP-1 products, and the FDA label for tirzepatide likewise advises against use with any other GLP-1 medication.
Which One Fits Your Situation?
The choice depends on your health history, your goals, your insurance, and what your provider recommends. If you have type 2 diabetes with kidney disease, for example, Ozempic’s approvals may be relevant, while some people may do better on tirzepatide’s stronger average results. Either way, these are long-term medications that work best alongside healthy habits.
New to the terminology? Our explainer on the difference between GLP-1 and GLP-1 receptor agonists is a good primer. This article is for general education and is not a substitute for personalized medical advice.
Frequently Asked Questions
Is Mounjaro Stronger Than Ozempic?
Milligrams cannot be compared across the two drugs, but in trials tirzepatide lowered A1C and body weight more than semaglutide.
Is Mounjaro Approved for Weight Loss?
Mounjaro is approved for type 2 diabetes. Zepbound, which contains the same active ingredient, is the version approved for weight management.
Can I Take Mounjaro and Ozempic Together?
No. Labels advise against combining a GLP-1 medication with another GLP-1 product.